ClinicalTrials.gg
TerminatedNCT06220669Updated Nov 12, 2026Results posted

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

A Phase 2 interventional study of LY3541860 and Placebo in Multiple Sclerosis, sponsored by Eli Lilly and Company. Terminated at 20 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
The interim analysis data failed to demonstrate the intended treatment effect.
Updated Nov 12, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 150 studies in Multiple Sclerosis with a site in Poland — 9 open to participants now, 30 under way, 18 of them phase 3. Multiple Sclerosis · Poland.

Enrollment
121st of 134
65 · median 435
Started
2024
with 3 others
Phase 2
35 of 150
3 open now
Registered
138th of 150
by date

Among the 150 studies in Multiple Sclerosis with a site in Poland, this one is the 121st largest by enrollment of the 134 interventional ones that give a count, is one of 4 that started in 2024, is one of 35 in phase 2, and was the 138th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 150 studies in Multiple Sclerosis with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Multiple Sclerosis with a site in Poland, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Relapsing remitting multiple sclerosis, Clinically isolated syndrome, Secondary progressive multiple sclerosis with disease activity.
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.
  • Participants must have 1 of these:

    • at least 1 documented relapse within the previous year
    • at least 2 documented relapses within the previous 2 years, or
    • at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.
  • Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (≤) 5.5 at screening and randomization.

Exclusion criteria

Exclusion Criteria:

  • Have had a diagnosis of:

    • primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or
    • nonactive secondary progressive MS ( Klineova and Lublin 2018).
  • Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).
  • Have a history of central nervous system (CNS) disease.
  • Have had a confirmed relapse with systemic administration \<30 days prior to randomization.
  • Have more than 20 active GdE brain lesions on screening MRI scan.
  • Have received any of these medications or treatments.
  • Have a current or recent acute, active infection.
  • Have current serious or unstable illnesses.
  • Have any other clinically important abnormality at screening or baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    LY3541860 High Dose

    Participants received a high dose of LY3541860 administered intravenously (IV) over a period of 36 weeks.

    Drug: LY3541860

  • Experimental
    Placebo / LY3541860 Low Dose

    Participants received LY3541860-matching placebo for 12 weeks, followed by a low dose of LY3541860 administered intravenously (IV) over a period of 24 weeks.

    Drug: LY3541860 · Drug: Placebo

Interventions

  • Administered IV

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions

    The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).

    Time frame: 12 Weeks

Secondary outcomes

  1. Cumulative Number of Total Number of T1 GdE Lesions

    The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).

    Time frame: 12 Weeks

  2. Cumulative Number of New and/or Enlarging T2 Lesions

    The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1).

    Time frame: 12 Weeks

  3. Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12

    Observed Plasma trough concentrations (Ctrough) of LY3541860.

    Time frame: Predose at Week 12

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneLY3541860 High DosePlacebo / LY3541860 Low Dose
Started3431
All participants who received at least 1 dose of the study intervention3431
Completed1312
Not completed2119
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject65
Withdrew: Study terminated by the sponsor1511
Withdrew: Protocol violation01
Withdrew: Physician decision01

Outcome measures

PrimaryCumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions

The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).

Time frame:
12 Weeks
Reported as:
Mean · Cumulative number of lesions
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
Cumulative number of lesionsLY3541860 High DosePlacebo / LY3541860 Low Dose
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions1.11 ± 0.3161.56 ± 0.791
Statistical analysis
  • LY3541860 High Dose vs Placebo / LY3541860 Low Dose · AIPW estimator · p = 0.531 · Relative reduction estimate from aipw: 0.29 · 90% CI -0.739 to 0.709
SecondaryCumulative Number of Total Number of T1 GdE Lesions

The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).

Time frame:
12 Weeks
Reported as:
Mean · Cumulative number of lesions
Cumulative Number of Total Number of T1 GdE Lesions
Cumulative number of lesionsLY3541860 High DosePlacebo / LY3541860 Low Dose
Cumulative Number of Total Number of T1 GdE Lesions1.38 ± 0.4011.82 ± 0.866
Statistical analysis
  • LY3541860 High Dose vs Placebo / LY3541860 Low Dose · AIPW estimator · p = 0.589 · Relative reduction estimate from aipw: 0.24 · 90% CI -0.769 to 0.676
SecondaryCumulative Number of New and/or Enlarging T2 Lesions

The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1).

Time frame:
12 Weeks
Reported as:
Mean · Cumulative number of lesions
Cumulative Number of New and/or Enlarging T2 Lesions
Cumulative number of lesionsLY3541860 High DosePlacebo / LY3541860 Low Dose
Cumulative Number of New and/or Enlarging T2 Lesions2.66 ± 0.8703.92 ± 1.954
Statistical analysis
  • LY3541860 High Dose vs Placebo / LY3541860 Low Dose · AIPW estimator · p = 0.506 · Relative reduction estimate from aipw: 0.32 · 90% CI -0.763 to 0.737
SecondaryPharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12

Observed Plasma trough concentrations (Ctrough) of LY3541860.

Time frame:
Predose at Week 12
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12
nanogram per milliliter (ng/mL)LY3541860 High Dose
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 1293300 ± 36.4

Adverse events

Collected over Baseline to End of Safety Follow-up (up to 60 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3541860 High Dose0/34 (0%)3/34 (8.8%)27/34 (79.4%)
Placebo / LY3541860 Low Dose0/31 (0%)2/31 (6.5%)21/31 (67.7%)
Most frequent serious events
Most frequent serious events
EventLY3541860 High DosePlacebo / LY3541860 Low Dose
Abnormal uterine bleedingReproductive system and breast disorders0/231/20
AppendicitisInfections and infestations0/341/31
Cardiac failureCardiac disorders1/340/31
Myocardial infarctionCardiac disorders1/340/31
PneumoniaInfections and infestations1/340/31
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/340/31
AsthmaRespiratory, thoracic and mediastinal disorders1/340/31
Most frequent other events
Showing 10 of 92
Most frequent other events
EventLY3541860 High DosePlacebo / LY3541860 Low Dose
NasopharyngitisInfections and infestations7/344/31
Upper respiratory tract infectionInfections and infestations4/344/31
Urinary tract infectionInfections and infestations3/344/31
FatigueGeneral disorders4/340/31
Pain in extremityMusculoskeletal and connective tissue disorders2/343/31
HeadacheNervous system disorders3/343/31
MyalgiaMusculoskeletal and connective tissue disorders3/341/31
ParaesthesiaNervous system disorders3/341/31
DiarrhoeaGastrointestinal disorders2/342/31
AstheniaGeneral disorders0/342/31

Baseline characteristics

All participants who received at least 1 dose of the study intervention.

Age, Continuous
Age, Continuous(years)LY3541860 High DosePlacebo / LY3541860 Low DoseTotal
Mean39.2 ± 11.4336.1 ± 10.5037.7 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)LY3541860 High DosePlacebo / LY3541860 Low DoseTotal
Female232043
Male111122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3541860 High DosePlacebo / LY3541860 Low DoseTotal
Hispanic or Latino101
Not Hispanic or Latino333063
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3541860 High DosePlacebo / LY3541860 Low DoseTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White343064
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)LY3541860 High DosePlacebo / LY3541860 Low DoseTotal
France303
Germany202
Italy033
Latvia224
Lithuania134
Poland201737
Slovakia112
United States5510
08

Study locations

20 sites
  • Panhandle Research and Medical Clinic
    Gulf Breeze, Florida 32561, United States
  • Conquest Research LLC - Winter Park - ClinEdge - PPDS
    Winter Park, Florida 32789, United States
  • Consultants in Neurology
    Northbrook, Illinois 60062, United States
  • Sharlin Health and Neurology
    Ozark, Missouri 65721-5315, United States
  • Premier Neurology
    Greer, South Carolina 29605, United States
  • Hope Neurology
    Knoxville, Tennessee 37922, United States
  • Centre Hospitalier Intercommunal - Site de Poissy
    Poissy, 78303, France
  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
    Milan, 20133, Italy
  • Pauls Stradins Clinical Univeristy Hospital
    Riga, LV-1002, Latvia
  • Neurocentrum Bydgoszcz sp. z o.o.
    Bydgoszcz, 85-796, Poland
  • Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala
    Katowice, 40-060, Poland
  • M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM
    Katowice, 40-571, Poland
  • NEURO-MEDIC Sp. z o. o.
    Katowice, 40-686, Poland
  • Clinirem
    Lublin, 20-064, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
    Poznan, 61-853, Poland
  • ETG Neuroscience - PPDS
    Warsaw, 02-677, Poland
  • IBISMED Wielospecjalistyczne Centrum Medyczne
    Zabrze, 41-800, Poland
  • ProNeuro Centrum Medyczne
    Żory, 44-240, Poland
  • Nemocnica Ruzinov
    Bratislava, 826 06, Slovakia
  • Queen's Medical Centre
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Oct 2025, 18 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Jan 24, 2024
StartActual
Mar 19, 2024
Primary completionActual
Oct 18, 2025
CompletionActual
Jul 13, 2026
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Enrollment
63→65
Nov 12, 2026
Interventions
Arms added: LY3541860 High Dose·Placebo / LY3541860 Low Dose; arms removed: LY3541860 Phase 2a Dose Level 1·LY3541860 Phase 2a Dose Level 2·Placebo Phase 2a·LY3541860 Phase 2b Dose Level 3·LY3541860 Phase 2b Dose Level 4·and 1 more
All 6

LY3541860 Phase 2a Dose Level 1 · LY3541860 Phase 2a Dose Level 2 · Placebo Phase 2a · LY3541860 Phase 2b Dose Level 3 · LY3541860 Phase 2b Dose Level 4 · Placebo Phase 2b

Nov 12, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionCumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions: how it is measured was reworded
Nov 12, 2026
Documents
Secondary outcomes
1 edited, 2 description edited
What changed in the outcomes
  • EditedPharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12Time frame: Baseline Through Week 12 → Predose at Week 12
  • DescriptionCumulative Number of New and/or Enlarging T2 Lesions: how it is measured was reworded
  • DescriptionCumulative Number of Total Number of T1 GdE Lesions: how it is measured was reworded
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Enrollment 63→65
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionCumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions: how it is measured was reworded
    Secondary outcomes 1 edited, 2 description edited
    What changed in the outcomes
    • EditedPharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12Time frame: Baseline Through Week 12 → Predose at Week 12
    • DescriptionCumulative Number of New and/or Enlarging T2 Lesions: how it is measured was reworded
    • DescriptionCumulative Number of Total Number of T1 GdE Lesions: how it is measured was reworded
    Interventions Arms added: LY3541860 High Dose·Placebo / LY3541860 Low Dose; arms removed: LY3541860 Phase 2a Dose Level 1·LY3541860 Phase 2a Dose Level 2·Placebo Phase 2a·LY3541860 Phase 2b Dose Level 3·LY3541860 Phase 2b Dose Level 4·and 1 more
    All 6

    LY3541860 Phase 2a Dose Level 1 · LY3541860 Phase 2a Dose Level 2 · Placebo Phase 2a · LY3541860 Phase 2b Dose Level 3 · LY3541860 Phase 2b Dose Level 4 · Placebo Phase 2b

    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06220669
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Mar 19, 2024
Primary completion
Oct 18, 2025
Completion
Jul 13, 2026
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevoloprubart

Start the discussion